Edwards’ Pursuit Of Transcatheter Mitral Valve Repair Options Continues, CEO Says
This article was originally published in The Gray Sheet
During the recent Wilson Sonsini Goodrich & Rosati Medical Device Conference in San Francisco, Edwards Lifesciences CEO Michael Mussallem offered candid remarks on his firm’s continued interest in developing a minimally invasive mitral valve repair product.
You may also be interested in...
Edwards is betting on next-generation Sapien devices and efforts towards a transcatheter mitral valve, as Medtronic and other competitors move closer to threatening the firm’s TAVR leadership position.
Abbott to present data showing MitraClip is safer option for inoperable patients.
Debuts include St. Jude’s Assura ICDs in Europe and Edwards’ Perimount mitral heart valve in China.